Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAK683 in Advanced Malignancies (Phase I/II, China)
CTR20201170Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MAK683 in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), T-cell lymphoma, nasopharyngeal carcinoma (NPC), gastric cancer (GC), sponsored by Novartis. Started Aug 2020; status: terminated.
02
Drugs
MAK683
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)T-cell lymphomanasopharyngeal carcinoma (NPC)gastric cancer (GC)
Beyond the preview
Go deeper on CTR20201170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201170.